Stock Analiz

Milestone Scientific Inc. MLSS

Industrial Specialties · IPO 2015 · data as of November 13, 2026

$0.31Market cap $28M
Open the interactive analysis →

Milestone Scientific Inc. (MLSS) is a healthcare company listed in the US with a market value of about $28M. In the twelve months to September 30, 2026 it had revenue of $9M and net income of -$4M, a net margin of -38.3%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 11% a year, a 5-year average ROIC of -88%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.

About Milestone Scientific

Milestone Scientific is listed in the US and classified in industrial specialties, IPO year 2015. Revenue went from $10M in 2014 to $9M in 2025, a decline of about 1.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 16% over three years (dilution for shareholders). It spends 5% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.0
P/B7.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-5.3%
Shareholder yield0.0%
Intrinsic value vs. price−93%

Growth and quality

Revenue growth (1 yr)4.0%
Revenue growth (5 yrs, per year)10.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-70.8%
ROIC (5-yr avg.)-88.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$9M$9M$9M$10M$9M$10M$5M$8M$10M$11M$10M
Net income-$4M-$6M-$5M-$7M-$9M-$7M-$7M-$8M-$7M-$5M-$6M
Free cash flow-$1M-$3M-$3M—-$6M-$4M-$7M-$2M-$2M-$1M-$5M
EPS (diluted)$-0.04$-0.07$-0.06$-0.10$-0.12$-0.10$-0.12$-0.16$-0.21$-0.16$-0.22
Net margin-38.3%-63.8%-54.6%-70.5%-98.9%-66.2%-134.9%-89.8%-77.2%-46.0%-56.7%
ROIC—-151.1%-87.3%-84.6%-82.5%-34.4%-34.4%-184.5%-370.4%-57.1%-76.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $1.25, 307% above the current price; targets range from $1.00 to $1.50; the consensus rating is “none”; expected EPS is $-0.04 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Milestone Scientific stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Milestone Scientific pay a dividend?

Not currently.

Is Milestone Scientific a good stock to buy?

We do not give buy or sell advice. Milestone Scientific scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.